TTR

Transthyretin · P02766 · TTR on Sugi Atlas →

137,527 patent compounds predicted against TTR, 84,695 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL68189	0.83	11/20
SCHEMBL69877	0.73	10/20
SCHEMBL70489	0.73	10/20
Diacerein (SCHEMBL25784)	1.00	9/20
Tolcapone (SCHEMBL33869)	1.00	8/20
SCHEMBL69226	0.68	8/20
SCHEMBL71110	0.68	8/20
Triclosan (SCHEMBL3269)	1.00	6/20
Resveratrol (SCHEMBL19425)	1.00	5/20
Resveratrol (SCHEMBL19426)	1.00	5/20
Caffeic Acid Phenethyl Ester (SCHEMBL93649)	1.00	5/20
SCHEMBL71021	0.88	5/20
SCHEMBL69236	0.64	5/20
SCHEMBL69237	0.64	5/20
SCHEMBL71118	0.58	5/20
SCHEMBL86351	0.55	5/20
Naringenin (SCHEMBL20570)	1.00	4/20
Naringenin (SCHEMBL20571)	1.00	4/20
Rhein (SCHEMBL25253)	1.00	4/20
Benzbromarone (SCHEMBL48993)	1.00	4/20

Clinical trials — most relevant to TTR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients	PHASE4	UNKNOWN
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)	PHASE3	COMPLETED
Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)	PHASE3	WITHDRAWN
Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy	PHASE1/PHASE2	RECRUITING
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis	PHASE1/PHASE2	COMPLETED
The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy	PHASE2	COMPLETED
Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)	nan	WITHDRAWN
ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers	nan	RECRUITING
TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects	nan	COMPLETED
Early and Systematic Screening in Chronic Neuropathy	nan	COMPLETED
Analysis of the Instestinal Microbiome of Patients With Transthyretin Amyloidosis	nan	UNKNOWN
Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry	nan	NOT_YET_RECRUITING
Increasing Amyloidosis Awareness and Diagnosis Through Programmatic Imaging, Blood/Urine Testing and Pathology	nan	UNKNOWN
The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.	nan	UNKNOWN
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis	nan	COMPLETED
Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)	nan	RECRUITING
New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis	nan	UNKNOWN
Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease	nan	UNKNOWN
Exploring Biomarkers in Hereditary Transthyretin Amyloidosis	nan	RECRUITING
Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy	nan	ACTIVE_NOT_RECRUITING
PET/CT Imaging in Carriers of TTR Mutations	nan	NOT_YET_RECRUITING
Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis	nan	UNKNOWN
PL_GNT01_ISR_Grant 53234273	nan	UNKNOWN
Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated)	nan	COMPLETED
Thyroid Function in Liver Cirrhosis: Is it Affected?	nan	COMPLETED
Carpal Tunnel Syndrome and Amyloid Cardiomyopathy	nan	COMPLETED
Prospective Evaluation of NfL as a Biomarker in ATTRv	nan	ACTIVE_NOT_RECRUITING
Screening for the Transthyretin-Related Familial Amyloidotic Polyneuropathy (TTR FAP)	nan	COMPLETED
Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders	nan	COMPLETED
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TTR binder may also engage these)

Protein	Name	Similarity
Q5U7I5	—	1.000	Q5U7I5 →
Q8HXW1	—	1.000	Q8HXW1 →
P12303	—	1.000	P12303 →
P49141	—	1.000	P49141 →
Q5NVS2	—	0.999	Q5NVS2 →
P50390	—	0.999	P50390 →
P02767	—	0.999	P02767 →
O46375	—	0.997	O46375 →
Q9MYN8	—	0.997	Q9MYN8 →
P49142	—	0.997	P49142 →
Q29616	—	0.997	Q29616 →
P49143	—	0.997	P49143 →
O55245	—	0.997	O55245 →
P30623	—	0.997	P30623 →
O46654	—	0.996	O46654 →
P07309	—	0.994	P07309 →
P42204	—	0.993	P42204 →
B7ZS96	—	0.993	B7ZS96 →
P07489	—	0.993	P07489 →
A4QNN7	—	0.993	A4QNN7 →
P31779	—	0.991	P31779 →
P27731	—	0.989	P27731 →
P81628	—	0.970	P81628 →
Q66K08	—	0.968	Q66K08 →
Q60963	—	0.968	Q60963 →
Q60629	—	0.967	Q60629 →
Q5ZJM3	—	0.967	Q5ZJM3 →
Q60432	—	0.967	Q60432 →
O35587	—	0.967	O35587 →
Q21265	—	0.967	Q21265 →